People with autoimmune skin diseases had significantly better cancer survival outcomes than others. Survival benefits were ...

Since then, its label has been expanded to include several indications, including moderate to severe plaque psoriasis (PsO), ...

Medically reviewed by Casey Gallagher, MD Eyebrow dandruff occurs when dead skin cells shed faster than usual. It causes white, yellow, or gray flakes around your brows. Seborrheic dermatitis, a skin ...

In fact, research shows that changing biologics is common. After two years, 1 in 4 people with psoriasis change from one biologic to another. Doing so can help improve your quality of life. Here ...

ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Patients with autoimmune skin diseases had improved survival after cancer treatment, suggesting a potential immunologic advantage and prompting further research into autoimmune-cancer interactions.

That’s where anti-inflammatory therapeutics come into play, offering hope for millions of people living with chronic inflammation. The global anti-inflammatory therapeutics market size was $98,026 ...

GAMMA Investing LLC lifted its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 367.8% during the 1st quarter, ...